Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2009 Jul;72(1):69-72.
doi: 10.5414/cnp72069.

Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome

Y Sawara  1 , M Itabashi, C Kojima, H Tabata, D Kamei, K Kawanishi, T Moriyama, H Sugiura, M Tsukada, T Takei, T Ogawa, T Yoshida, J Arai, K Uchida, K Tsuchiya, K Nitta
Affiliations
Case Reports

Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome

Y Sawara et al. Clin Nephrol. 2009 Jul.

Abstract

Minimal change nephrotic syndrome (MCNS) usually is considered to have a good renal prognosis, but the frequency of relapses is a therapeutic challenge to physicians. The treatment of patients with multiple relapses remains a matter of controversy, because few controlled studies are available. We report the case of a 25-year-old man who experienced relapses of MCNS. Single-dose rituximab therapy (total dose 500 mg) was given during the fourth relapse. Complete remission occurred 10 days later, when no CD19/20-positive B cells were detected in the blood. This the first report of efficacy of single-dose rituximab therapy to treat multi-relapsing MCNS in an adult patient.

PubMed Disclaimer

Publication types